Genentech, a member of the Roche Group, announced results from the Phase III IMpower132 study of TECENTRIQ plus pemetrexed and platinum-based chemotherapy for the initial treatment of people with non-squamous, non-small cell lung cancer. This interim analysis showed that TECENTRIQ and chemotherapy reduced the risk of disease worsening or death by 40% compared with chemotherapy alone. While a numerical improvement of 4.5 months for the co-primary endpoint of overall survival was observed, at this interim analysis statistical significance has not yet been met. The study will continue as planned, with final OS results expected next year. Safety for the TECENTRIQ and chemotherapy combination appeared consistent with the known safety profile of the individual medicines, and no new safety signals were identified with the combination. “This is our third Phase III trial in non-squamous non-small cell lung cancer demonstrating that a TECENTRIQ-based regimen can help reduce the risk of disease progression for people living with this disease,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “We will discuss these results with health authorities globally.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.